Article
Malassezia Folliculitis following Triple Therapy for Cystic Fibrosis.
Medicina (Kaunas, Lithuania) - 2 Sept 2022
Li Pomi Federica, Di Bartolomeo Luca, Vaccaro Mario, Lentini Maria, Cristadoro Simona, Lucanto Maria Cristina, Lombardo Mariangela, Costa Stefano, Borgia Francesco
Abstract excerpt
Triple-combination therapy with elexacaftor, tezacaftor and ivacaftor has been recently approved for cystic fibrosis patients with at least one F508del mutation in the transmembrane conductance regulator of the cystic fibrosis gene. Among the adverse events of elexacaftor, tezacaftor and ivacaftor, the cutaneous ones have been rarely reported, mainly dealing with urticarial-like rashes. On this topic, we report...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.